NICE approves Rituxan for first-line treatment of follicular lymphoma

Submitted by Ross Bonander Wed 01/25/2012

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

In a coup for Roche and a victory for follicular lymphoma patients in the United Kingdom, Rituxan (known in the UK as MabThera) has been approved for use on the UK's National Health Service for the first-line treatment of follicular lymphoma.

The approval comes after months of consideration given by the National Institute for Health and Clinical Excellence (NICE).

Prior to this, Rituxan was only approved for UK follicular lymphoma patients if their disease had returned. Now, they may receive it in a maintenance setting as a first-line therapy.

Source: Dow Jones Newswires

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.